Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis.

Hao-Xiang WuYi-Qian PanYe HeZi-Xian WangWen-Long GuanYan-Xing ChenYi-Chen Yao Ning-Yi Shao Rui-Hua Xu Feng-Hua Wang

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)

This study provided novel evidence supporting the superiority of PD-1 antibody plus chemotherapy to chemotherapy alone in patients with advanced ESCC with low PD-L1 expression. Further studies of predictive biomarkers are warranted.

Keyphrases

locally advanced
chemotherapy induced
squamous cell carcinoma
case control